NEWS

First-line immunotherapy treatment can improve survival for subset of lung cancer patients
Science Daily
In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced “nye VOL ue mab,” marketed at Opdivo), with standard-of-care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung …

and more »